Paraganglioma classification: Difference between revisions
Asem Juhani (talk | contribs) No edit summary |
Asem Juhani (talk | contribs) |
||
Line 9: | Line 9: | ||
==Classification== | ==Classification== | ||
There are several way to classify pheochromocytomas and paragangliomas (PPGLs), including: | |||
PPGLs may be classified according to their site of origin into: | PPGLs may be classified according to their site of origin into: | ||
Line 14: | Line 16: | ||
*Paraganglioma: tumor originates from chromaffin cells in extra-adrenal neural ganglia. (15-20%) These can have a sympathetic origin (sympathetic chain in thorax, abdomen and pelvis) or a parasympathetic origin (in neck, head and skull base). | *Paraganglioma: tumor originates from chromaffin cells in extra-adrenal neural ganglia. (15-20%) These can have a sympathetic origin (sympathetic chain in thorax, abdomen and pelvis) or a parasympathetic origin (in neck, head and skull base). | ||
Both pheochromocytomas and paragangliomas may be classified into 3 subcategories based on spread: | |||
* | *Local. | ||
* | *Regional. | ||
* | *Metastatic. | ||
These 3 categories share the same histological and biochemical characteristics. Metastasis is considered the definition of malignancy in PPGLs. Non-metastatic PPGLs are considered benign. | |||
[Disease name] may be classified into several subtypes based on: | [Disease name] may be classified into several subtypes based on: |
Revision as of 15:10, 13 February 2019
Paraganglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Paraganglioma classification On the Web |
American Roentgen Ray Society Images of Paraganglioma classification |
Risk calculators and risk factors for Paraganglioma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Pheochromocytomas and paragnagliomas (collectively referred to as PPGLs) are rare tumors that originate from chromaffin cells in the adrenal medulla (pheochromocytoma) and extra-adrenal neural ganglia (paraganglioma). These tumors can be biochemically active (producing catecholamines) or silent. PPGLs can also be classified as either sporadic or familial, with association extablished to several familial syndromes.
PPGLs can be either benign or malignant. However, the definition of malignancy is established by the presence of metastasis as benign and malignant tumors in this category are indistinguishable in their histological and biochemical characteristics. Extent of spread of tumor is another factor that classifies PPGLs, putting them into the categories of local, regional and metastatic.
Classification
There are several way to classify pheochromocytomas and paragangliomas (PPGLs), including:
PPGLs may be classified according to their site of origin into:
- Pheochromocytoma: tumor originates from chromaffin cells in the adrenal medulla. (80-85%)
- Paraganglioma: tumor originates from chromaffin cells in extra-adrenal neural ganglia. (15-20%) These can have a sympathetic origin (sympathetic chain in thorax, abdomen and pelvis) or a parasympathetic origin (in neck, head and skull base).
Both pheochromocytomas and paragangliomas may be classified into 3 subcategories based on spread:
- Local.
- Regional.
- Metastatic.
These 3 categories share the same histological and biochemical characteristics. Metastasis is considered the definition of malignancy in PPGLs. Non-metastatic PPGLs are considered benign.
[Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].